[info / IR email for company]

Discover our strategy

Stay Ahead with Maxonis Updates

Subscribe to our newsletter for company updates!

Why Investors Choose Maxonis

First-in-class Nerve Regeneration Platform
LDP-916 is a peptide–hydrogel therapy designed to actively regenerate nerve tissue rather than simply bridge damaged nerves.
Large Unmet Markets in PNI and SCI
Targeting peripheral nerve injury and spinal cord injury addresses areas where current treatments often fail to restore meaningful
function.
Strong Preclinical Accomplishments
Encouraging animal-model results show functional recovery signals across PNI and SCI programs.
Scientific and Commercial Leadership
The team combines nerve-repair science, biomaterials innovation, and prior health-tech commercialization experience.

Ready to Learn More?

Join a growing base of investors who engage with Maxonis. Connect with our team or access our latest investor materials today.

Disclaimer

All investing is subject to risk, including the possible loss of the money you invest.

These statements should not be construed as, (i) an offer to sell or a solicitation of an offer to buy any security, or (ii) investment, tax, legal, or other advice. Any such offer or solicitation will be made only by means of an offering document that meets all applicable legal requirements.

Statements contained herein that are not historical facts, including statements regarding objectives, strategies, and performance targets, may constitute forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in such statements. Past performance is not necessarily indicative of, and cannot be relied upon as a guarantee of, future results. Investors should consult their own advisors with respect to any investment decision.

Terms & Use